Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Ageing Research Reviews · 2023-08 · 89 · 101979
DOI: 10.1016/j.arr.2023.101979 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023-08. Verfasst von Joseph Nowell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Sciences, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Alzheimer Disease, Diabetes Mellitus, Type 2, Neurodegenerative Diseases. Die Arbeit wurde bisher 177-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cardiff University.
Themen: Demenz
Abstract (Originalsprache)
Therapeutic strategies for neurodegenerative disorders have commonly targeted individual aspects of the disease pathogenesis to little success. Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by several pathological features. In AD and PD, there is an abnormal accumulation of toxic proteins, increased inflammation, decreased synaptic function, neuronal loss, increased astrocyte activation, and perhaps a state of insulin resistance. Epidemiological evidence has revealed a link between AD/PD and type 2 diabetes mellitus, with these disorders sharing some pathological commonalities. Such a link has opened up a promising avenue for repurposing antidiabetic agents in the treatment of neurodegenerative disorders. A successful therapeutic strategy for AD/PD would likely require a single or several agents which target the separate pathological processes in the disease. Targeting cerebral insulin signalling produces numerous neuroprotective effects in preclinical AD/PD brain models. Clinical trials have shown the promise of approved diabetic compounds in improving motor symptoms of PD and preventing neurodegenerative decline, with numerous further phase II trials and phase III trials underway in AD and PD populations. Alongside insulin signalling, targeting incretin receptors in the brain represents one of the most promising strategies for repurposing currently available agents for the treatment of AD/PD. Most notably, glucagon-like-peptide-1 (GLP-1) receptor agonists have displayed impressive clinical potential in preclinical and early clinical studies. In AD the GLP-1 receptor agonist, liraglutide, has been demonstrated to improve cerebral glucose metabolism and functional connectivity in small-scale pilot trials. Whilst in PD, the GLP-1 receptor agonist exenatide is effective in restoring motor function and cognition. Targeting brain incretin receptors reduces inflammation, inhibits apoptosis, prevents toxic protein aggregation, enhances long-term potentiation and autophagy as well as restores dysfunctional insulin signalling. Support is also increasing for the use of additional approved diabetic treatments, including intranasal insulin, metformin hydrochloride, peroxisome proliferator-activated nuclear receptor γ agonists, amylin analogs, and protein tyrosine phosphatase 1B inhibitors which are in the investigation for deployment in PD and AD treatment. As such, we provide a comprehensive review of several promising anti-diabetic agents for the treatment of AD and PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Brain Sciences, Imperial College London, London, UK.
- Department of Brain Sciences, Imperial College London, London, UK; School of Medicine, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK. Electronic address: paul.edison@imperial.ac.uk.
Förderung
- Cardiff University
Zitieren
APA
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023). Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Research Reviews, 89, 101979. https://doi.org/10.1016/j.arr.2023.101979
Vancouver
Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease. Ageing Research Reviews. 2023;89:101979. doi:10.1016/j.arr.2023.101979
BibTeX
@article{Nowell2023,
author = {Nowell, Joseph and Blunt, Eleanor and Gupta, Dhruv and Edison, Paul},
title = {Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease},
journal = {Ageing Research Reviews},
year = {2023},
volume = {89},
pages = {101979},
doi = {10.1016/j.arr.2023.101979}
}
EUVIMED